Physician profile
Mary Mcafee
NPI 1336482835
$6,031.43
in general payments reported to CMS, 2019-2025
22 companies · $654 in 2025
The $654 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $739 · 2022: $1,501 · 2023: $1,543 · 2024: $1,472 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,668.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $599.43 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.10 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $551.42 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.87 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $509.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $278.09 | 2020-2025 | Dificid, Verquvo, Zerbaxa |
| Gilead Sciences, INC. | $264.59 | 2021-2023 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.85 | 2020-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $236.39 | 2022-2024 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $205.41 | 2021-2024 | Fasenra, Farxiga |
| Alexion Pharmaceuticals, INC. | $200.64 | 2021-2025 | Ultomiris |
| Boston Scientific Corporation | $191.84 | 2020-2024 | Watchman Flx, Watchman Access System |
| Paratek Pharmaceuticals, INC. | $185.23 | 2021-2024 | Nuzyra |
| Philips North America LLC | $95.29 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $80.62 | 2021-2024 | Eliquis |
| Melinta Therapeutics, LLC | $66.82 | 2022 | |
| Electromed, INC. | $42.09 | 2022-2024 | Smartvest |
| Scpharmaceuticals INC. | $30.03 | 2024 | |
| Inari Medical, INC. | $28.06 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $20.01 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.